title: Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
abstract: Owing to its beneficial pharmacological profile, the low-molecular-weight heparin (LMWH) enoxaparin is increasingly being taken as an alternative to UFH in the treatment of ACS with an early invasive strategy and in elective percutaneous coronary interventions (PCI). Insufficient anticoagulation increases the risk of catheter thrombus formation during PCI. The aim of the present study was to test in vitro the hypotheses that (i) inhibiting thrombin or thrombin generation by administering LMWH is a critical intervention in preventing catheter thrombus formation and (ii) other LMWH such as certoparin or dalteparin are as effective as enoxaparin. Blood pre-treated with the anticoagulants of interest was continuously circulated through a guiding catheter by using a roller pump for a maximum experimental period of 60 min or until the catheter became occluded. Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints. All LMWH tested significantly reduced catheter thrombus generation comparable to UFH treatment whereas there was no difference between the specific LMWH with respect to catheter thrombus formation or deposition of platelets, erythrocytes and fibrin. Thrombus generation was found to negatively correlate with anti-Xa activity. The additional use of eptifibatide did not affect thrombus formation. These data suggest that modulating plasmatic coagulation by employing LMWH is critical for preventing catheter thrombus formation and at the same time offer a potential for administering LMWH other than enoxaparin, such as certoparin or dalteparin, in the setting of PCI.
authors.affiliation: Department of Medicine III, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Str. 40, 06097, Halle (Saale), Germany. uwe.raaz@medizin.uni-halle.de
authors.forename: Uwe
authors.initials: U
authors.lastname: Raaz
authors.forename: Michael
authors.initials: M
authors.lastname: Buerke
authors.forename: Marese
authors.initials: M
authors.lastname: Busshardt
authors.forename: Lars
authors.initials: L
authors.lastname: Maegdefessel
authors.forename: Alexander
authors.initials: A
authors.lastname: Plehn
authors.forename: Baerbel
authors.initials: B
authors.lastname: Hauroeder
authors.forename: Karl
authors.initials: K
authors.lastname: Werdan
authors.forename: Axel
authors.initials: A
authors.lastname: Schlitt
mesh_terms: D006328:Cardiac Catheterization / Q000009:adverse effects*; D017985:Dalteparin / Q000627:therapeutic use*; D017984:Enoxaparin / Q000627:therapeutic use*; D006331:Heart Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin; C403769:certoparin